


In the claims:

Please cancel claims 2 through 16 inclusive.

Please add new claims 17 through 32 as follows:


- sub
C3
17. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphoneutrophil (PMN) inflammation in a subject is modulated.

18. (New) The method of claim 17, wherein said method is performed *in vitro*.
19. (New) The method of claim 17, wherein said method is performed *in vivo*.


20. (New) A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.

21. (New) The method of claim 20, wherein said method is performed *in vitro*.
22. (New) The method of claim 20, wherein said method is performed *in vivo*.


23. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.


24. (New) The method of claim 23, wherein said method is performed *in vitro*.
25. (New) The method of claim 23, wherein said method is performed *in vivo*.

- Sub C3
26. (New) A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

27. (New) The method of claim 26, wherein said method is performed *in vitro*.
28. (New) The method of claim 26, wherein said method is performed *in vivo*.
29. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:
a container holding a therapeutically effective amount of at least one lipoxin compound having the formula




wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

30. (New) A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and


instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

Application Number: Pending

Docket: 7214.08

31. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:


a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

32. (New) A packaged pharmaceutical composition for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:
a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and
instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.

REMARKS

Claims 1 and 17 through 32 are pending.

The specification has been amended to correct for an obvious typographical errors on pages 11, 14, 17 and 19 and to more clearly define the invention.

Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version with Markings to Show Changes Made."